Abstract

BackgroundThe two leading causes of death in SSc are PAH and ILD. Historically, survival is worse in patients with combined PAH-ILD compared with isolated PAH (1), and there may not...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Pulmonary Hypertension: From an Orphan Disease to a Public Health Problem
Nikolai Khaltaev ... Marc Humbert
Chest | VOL. 132
Nikolai Khaltaev, et. al.Nikolai Khaltaev ... Marc Humbert
01 Aug 2007
PH-ILD: Identification, Evaluation, and Monitoring: A Diagnostic View From Both Sides
Farbod N Rahaghi ... Franck F Rahaghi
Advances in Pulmonary Hypertension | VOL. 20
Farbod N Rahaghi, et. al.Farbod N Rahaghi ... Franck F Rahaghi
01 Oct 2021
Sildenafil for Pulmonary Arterial Hypertension: Exciting, But Protection Required
Sanjay Mehta
Chest | VOL. 123
Sanjay MehtaSanjay Mehta
01 Apr 2003
A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE AND PULMONARY HYPERTENSION
Ankush Ratwani ... Christopher King
Chest | VOL. 158
Ankush Ratwani, et. al.Ankush Ratwani ... Christopher King
01 Oct 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers